SEC Form 4 · accession 0001193125-26-292956
Pharvaris N.V. · PHVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anne Lesage
Officer — Chief Early Development
Period of report
Jun 29, 2026
Accepted (ET)
Jul 1, 2026 · 7:02 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001830487
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 29, 2026 | M | 1,400 | $2.59 | A | 57,850 | D | |
| Common Stock | Jun 29, 2026 | M | 900 | $8.05 | A | 58,750 | D | |
| Common Stock | Jun 29, 2026 | M | 4,100 | $2.59 | A | 56,450 | D | |
| Common Stock | Jun 29, 2026 | M | 4,200 | $8.05 | A | 67,050 | D | |
| Common StockF2 | Jun 29, 2026 | S | 2,300 | $35.1242 | D | 56,450 | D | |
| Common StockF3 | Jun 29, 2026 | S | 8,300 | $35.0491 | D | 58,750 | D | |
| Common Stock | Jun 30, 2026 | M | 2,972 | $2.59 | A | 61,722 | D | |
| Common Stock | Jun 30, 2026 | M | 24,900 | $8.05 | A | 86,622 | D | |
| Common StockF4 | Jun 30, 2026 | S | 27,872 | $35.4797 | D | 58,750 | D | |
| Common StockF6,F7 | Jun 29, 2026 | S | 6,997 | $35.0481 | D | 124,672 | I | By GrayMatters Consulting BVBA |
| Common StockF8,F7 | Jun 30, 2026 | S | 30,703 | $35.4896 | D | 93,969 | I | By GrayMatters Consulting BVBA |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F9 | $8.05 | Jun 29, 2026 | M | 4,200 | D | — | Apr 6, 2033 | Common Stock | 4,200 | 69,900 | D |
| Stock Option (Right to Buy)F9 | $8.05 | Jun 30, 2026 | M | 24,900 | D | — | Apr 6, 2033 | Common Stock | 24,900 | 45,000 | D |
| Stock Option (Right to Buy)F10 | $2.59 | Jun 29, 2026 | M | 1,400 | D | — | Jan 1, 2030 | Common Stock | 1,400 | 7,072 | D |
| Stock Option (Right to Buy)F10 | $2.59 | Jun 29, 2026 | M | 4,100 | D | — | Jan 1, 2030 | Common Stock | 4,100 | 2,972 | D |
| Stock Option (Right to Buy)F10 | $2.59 | Jun 30, 2026 | M | 2,972 | D | — | Jan 1, 2030 | Common Stock | 2,972 | 0 | D |
Explanation of responses
- F1This is a scheduled exercise and sale from 10b5-1 trading plan.
- F1025% of the option vested on January 1, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.
- F2The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to $35.30. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F3The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to 35.12. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F4The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to $35.84. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F5This is a scheduled sale from 10b5-1 trading plan.
- F6The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The sales prices for the transactions ranged from $35.00 to $35.12. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F7GrayMatters Consulting B.V., an entity controlled by Dr. Lesage
- F8The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The sales prices for the transactions ranged from $35.00 to $35.86. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F925% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.